

# Flavia Niccolini

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7563903/publications.pdf>

Version: 2024-02-01

39  
papers

1,861  
citations

257450

24  
h-index

289244

40  
g-index

41  
all docs

41  
docs citations

41  
times ranked

2871  
citing authors

#	ARTICLE	IF	CITATIONS
1	The role of phosphodiesterase 4 in excessive daytime sleepiness in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2020, 77, 163-169.	2.2	11
2	Predict cognitive decline with clinical markers in Parkinson's disease (PRECODE-1). <i>Journal of Neural Transmission</i> , 2020, 127, 51-59.	2.8	6
3	Dysphagia is associated with presynaptic dopaminergic dysfunction and greater non-motor symptom burden in early drug-naïve Parkinson's disease patients. <i>PLoS ONE</i> , 2019, 14, e0214352.	2.5	12
4	Sleep disturbances and gastrointestinal dysfunction are associated with thalamic atrophy in Parkinson's disease. <i>BMC Neuroscience</i> , 2019, 20, 55.	1.9	9
5	Cortical thinning across Parkinson's disease stages and clinical correlates. <i>Journal of the Neurological Sciences</i> , 2019, 398, 31-38.	0.6	51
6	Comparison of phosphodiesterase 10A and dopamine transporter levels as markers of disease burden in early Parkinson's disease. <i>Movement Disorders</i> , 2019, 34, 1505-1515.	3.9	15
7	Speech difficulties in early de novo patients with Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2019, 64, 256-261.	2.2	26
8	Predicting cognitive decline with non-clinical markers in Parkinson's disease (PRECODE-2). <i>Journal of Neurology</i> , 2019, 266, 1203-1210.	3.6	14
9	Diabetes mellitus and Parkinson disease. <i>Neurology</i> , 2018, 90, e1654-e1662.	1.1	158
10	The serotonergic system in Parkinson's disease patients with dyskinesia: evidence from imaging studies. <i>Journal of Neural Transmission</i> , 2018, 125, 1217-1223.	2.8	26
11	Increased dopaminergic function in the thalamus is associated with excessive daytime sleepiness. <i>Sleep Medicine</i> , 2018, 43, 25-30.	1.6	12
12	Excessive daytime sleepiness may be associated with caudate denervation in Parkinson disease. <i>Journal of the Neurological Sciences</i> , 2018, 387, 220-227.	0.6	51
13	Striatal molecular alterations in HD gene carriers: a systematic review and meta-analysis of PET studies. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 185-196.	1.9	18
14	Molecular Imaging of the Dopaminergic System in Idiopathic Parkinson's Disease. <i>International Review of Neurobiology</i> , 2018, 141, 131-172.	2.0	18
15	PDE10A and ADCY5 mutations linked to molecular and microstructural basal ganglia pathology. <i>Movement Disorders</i> , 2018, 33, 1961-1965.	3.9	38
16	Disease-related patterns of in vivo pathology in Corticobasal syndrome. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 2413-2425.	6.4	26
17	Urinary dysfunction in early de novo patients with Parkinson's disease. <i>Movement Disorders</i> , 2017, 32, 939-940.	3.9	9
18	Imaging in Parkinson's Disease. <i>International Review of Neurobiology</i> , 2017, 132, 233-274.	2.0	21

#	ARTICLE	IF	CITATIONS
19	Serotonin transporter in Parkinson's disease: A meta-analysis of positron emission tomography studies. <i>Annals of Neurology</i> , 2017, 81, 171-180.	5.3	77
20	Loss of phosphodiesterase 4 in Parkinson disease. <i>Neurology</i> , 2017, 89, 586-593.	1.1	30
21	Molecular Imaging Markers to Track Huntington's Disease Pathology. <i>Frontiers in Neurology</i> , 2017, 8, 11.	2.4	44
22	Parkinson's Disease, Diabetes and Cognitive Impairment. <i>Recent Patents on Endocrine, Metabolic &amp; Immune Drug Discovery</i> , 2016, 10, 11-21.	0.6	52
23	Current status of PET imaging in Huntington's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 1171-1182.	6.4	66
24	Loss of extra-striatal phosphodiesterase 10A expression in early premanifest Huntington's disease gene carriers. <i>Journal of the Neurological Sciences</i> , 2016, 368, 243-248.	0.6	37
25	A systematic review of lessons learned from PET molecular imaging research in atypical parkinsonism. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 2244-2254.	6.4	37
26	Imaging in Parkinson's disease. <i>Clinical Medicine</i> , 2016, 16, 371-375.	1.9	110
27	Cholinergic imaging in dementia spectrum disorders. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 1376-1386.	6.4	87
28	Phosphodiesterase 10A in Schizophrenia: A PET Study Using [ <sup>11</sup> C]IMA107. <i>American Journal of Psychiatry</i> , 2016, 173, 714-721.	7.2	33
29	Altered PDE10A expression detectable early before symptomatic onset in Huntington's disease. <i>Brain</i> , 2015, 138, 3016-3029.	7.6	90
30	Morphometric changes in the reward system of Parkinson's disease patients with impulse control disorders. <i>Journal of Neurology</i> , 2015, 262, 2653-2661.	3.6	41
31	Molecular imaging of levodopa-induced dyskinesias. <i>Cellular and Molecular Life Sciences</i> , 2015, 72, 2107-2117.	5.4	18
32	Loss of phosphodiesterase 10A expression is associated with progression and severity in Parkinson's disease. <i>Brain</i> , 2015, 138, 3003-3015.	7.6	100
33	PET in Multiple Sclerosis. <i>Clinical Nuclear Medicine</i> , 2015, 40, e46-e52.	1.3	20
34	Recent imaging advances in neurology. <i>Journal of Neurology</i> , 2015, 262, 2182-2194.	3.6	33
35	Increased central microglial activation associated with peripheral cytokine levels in premanifest Huntington's disease gene carriers. <i>Neurobiology of Disease</i> , 2015, 83, 115-121.	4.4	133
36	Serotonin in Parkinson's disease. <i>Behavioural Brain Research</i> , 2015, 277, 136-145.	2.2	224

#	ARTICLE	IF	CITATIONS
37	Dopamine receptor mapping with PET imaging in Parkinson's disease. Journal of Neurology, 2014, 261, 2251-2263.	3.6	45
38	Neuroimaging in Huntington's disease. World Journal of Radiology, 2014, 6, 301.	1.1	60
39	BC-12 and its potential for the prevention of relapse in multiple sclerosis. Degenerative Neurological and Neuromuscular Disease, 2012, 2, 119.	1.3	2